ANIK Anika Therapeutics Inc

Price (delayed)

$40.41

Market cap

$582.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$505.73M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights

Anika Therapeutics's debt has shrunk by 72% YoY and by 2.3% QoQ

The net income has surged by 53% since the previous quarter

Anika Therapeutics's quick ratio has decreased by 49% YoY but it has increased by 19% from the previous quarter

Anika Therapeutics's gross margin has decreased by 13% YoY but it has increased by 4.3% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.anikatherapeutics.com

Peers: MDT SYK HRC JNJ

Key stats

What are the main financial stats of ANIK

Market

Shares outstanding

14.42M

Market cap

$582.83M

Enterprise value

$505.73M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.03

Price to sales (P/S)

4.25

EV/EBIT

N/A

EV/EBITDA

5,682.4

EV/Sales

3.7

Earnings

Revenue

$136.82M

EBIT

-$15.65M

EBITDA

$89,000

Free cash flow

$6.86M

Per share

EPS

-$0.9

Free cash flow per share

$0.48

Book value per share

$19.93

Revenue per share

$9.51

TBVPS

$18.61

Balance sheet

Total assets

$363.13M

Total liabilities

$76.33M

Debt

$20.08M

Equity

$286.8M

Working capital

$136.39M

Liquidity

Debt to equity

0.07

Current ratio

4.3

Quick ratio

3.06

Net debt/EBITDA

-866.3

Margins

EBITDA margin

0.1%

Gross margin

55.5%

Net margin

-9.3%

Operating margin

-30.9%

Efficiency

Return on assets

-3.4%

Return on equity

-4.5%

Return on invested capital

-9.7%

Return on capital employed

-4.9%

Return on sales

-11.4%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time

Intraday

1.99%

1 week

3.38%

1 month

-4.15%

1 year

18.09%

YTD

-10.72%

QTD

-6.65%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time

Revenue

$136.82M

Gross profit

$75.87M

Operating income

-$42.25M

Net income

-$12.7M

Gross margin

55.5%

Net margin

-9.3%

Anika Therapeutics's net margin has surged by 55% QoQ

The net income has surged by 53% since the previous quarter

Anika Therapeutics's gross margin has decreased by 13% YoY but it has increased by 4.3% from the previous quarter

The company's gross profit rose by 10% QoQ but it fell by 4.9% YoY

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation

P/E

N/A

P/B

2.03

P/S

4.25

EV/EBIT

N/A

EV/EBITDA

5,682.4

EV/Sales

3.7

The company's EPS has surged by 52% QoQ

ANIK's price to book (P/B) is 17% less than its 5-year quarterly average of 2.4 and 5% less than its last 4 quarters average of 2.1

ANIK's equity is up by 3.7% since the previous quarter

ANIK's P/S is 24% below its 5-year quarterly average of 5.5 and 7% below its last 4 quarters average of 4.5

The revenue has grown by 9% YoY and by 6% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance

The company's return on sales has surged by 57% QoQ

Anika Therapeutics's ROE has soared by 53% from the previous quarter

The return on assets has surged by 50% since the previous quarter

The ROIC is up by 48% since the previous quarter

Dividends

What is ANIK's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time

Anika Therapeutics's total liabilities has decreased by 50% YoY and by 11% from the previous quarter

Anika Therapeutics's quick ratio has decreased by 49% YoY but it has increased by 19% from the previous quarter

Anika Therapeutics's debt is 93% lower than its equity

Anika Therapeutics's debt has shrunk by 72% YoY and by 2.3% QoQ

The debt to equity has dropped by 72% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.